Sign in

You're signed outSign in or to get full access.

Matt Roden

former Executive Director and Senior Analyst at UBS Investment Bank

Matthew Roden, Ph.D. is a former Executive Director and Senior Analyst at UBS Investment Bank, where he served as Head of Global Biotechnology Equity Research, leading coverage of US and global biotechnology stocks. He provided equity research on numerous biotech companies and supported 24 equity offerings totaling $3.3 billion in initial value from 2005-2016, though specific performance metrics such as success rates or TipRanks rankings are not publicly detailed. Roden joined UBS in 2010 from Bank of America Merrill Lynch, where he was a Vice President and Senior Analyst, following prior roles as a Senior Equity Analyst at J.P. Morgan and Associate at Credit Suisse First Boston. He holds a PhD in Microbiology and Immunology from Albert Einstein College of Medicine and was a pre-doctoral fellow at the National Cancer Institute; no specific FINRA registrations or securities licenses are listed in available records.

Matt Roden's questions to Chefs' Warehouse (CHEF) leadership

Question · Q4 2025

Matt Roden asked about the impact of extreme winter weather on year-to-date sales versus expectations and the drivers of operating expense leverage implied by the full-year guidance.

Answer

Jim Leddy, CFO, explained that January was strong, and while the storm temporarily impacted the first fiscal week of February, the second week bounced back nicely. Regarding operating expense leverage, Mr. Leddy stated that the company focuses on growing gross profit dollars higher than adjusted operating expenses year-over-year, and the guidance reflects various levels of volume, product mix changes, and market factors, but good operating leverage is still expected.

Ask follow-up questions

Fintool

Fintool can predict Chefs' Warehouse logo CHEF's earnings beat/miss a week before the call